We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
+51.2%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.01B
AUM Growth
+$676M
Cap. Flow
-$168M
Cap. Flow %
-5.59%
Top 10 Hldgs %
75.26%
Holding
119
New
16
Increased
18
Reduced
26
Closed
23

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$54.2M
2
SRRK icon
Scholar Rock
SRRK
+$27.3M
3
ARWR icon
Arrowhead Research
ARWR
+$27.2M
4
PRTA icon
Prothena Corp
PRTA
+$19.3M
5
KRRO icon
Korro Bio
KRRO
+$13.8M

Top Sells

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$114M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$46.9M
3
IMGN
Immunogen Inc
IMGN
+$24M
4
FOLD
Amicus Therapeutics
FOLD
+$23.1M
5
RVMD icon
Revolution Medicines
RVMD
+$20M

Sector Composition

Rank Sector Weight
1 Healthcare 50.36%
2 Consumer Discretionary 46.45%
3 Miscellaneous 2.48%
4 Technology 0.44%
5 Real Estate 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRWD icon
101
CrowdStrike
CRWD
$248B
– –
-8,000
Closed -$335K
DAWN
102
DELISTED
Day One Biopharmaceuticals
DAWN
– –
-500,000
Closed -$6.13M
GERN icon
103
Geron
GERN
$842M
– –
-5,565,889
Closed -$11.8M
NBP
104
NovaBridge Biosciences American Depositary Shares
NBP
$184M
– –
-850,000
Closed -$1.12M
LVTX
105
DELISTED
LAVA Therapeutics
LVTX
– –
-200,000
Closed -$294K
NBTX
106
Nanobiotix
NBTX
$1.79B
– –
-1,000,000
Closed -$8.75M
NFLX icon
107
Netflix
NFLX
$324B
– –
-12,850
Closed -$485K
NTLA icon
108
Intellia Therapeutics
NTLA
$1.59B
– –
-276,077
Closed -$8.73M
PLRX icon
109
Pliant Therapeutics
PLRX
$69.4M
– –
-1,490
Closed -$26K
RNAM
110
DELISTED
Avidity Biosciences
RNAM
– –
-300,000
Closed -$1.91M
VERV
111
DELISTED
Verve Therapeutics
VERV
– –
-300,000
Closed -$3.98M
VRDN icon
112
Viridian Therapeutics
VRDN
$2.47B
– –
-504,978
Closed -$7.75M
VTYX
113
DELISTED
Ventyx Biosciences
VTYX
– –
-405,239
Closed -$14.1M
XYZ
114
Block Inc
XYZ
$47B
– –
-15,500
Closed -$686K
KA
115
DELISTED
Kineta, Inc. Common Stock
KA
– –
-31,055
Closed -$106K
RYZB
116
DELISTED
RayzeBio, Inc. Common Stock
RYZB
– –
-555,556
Closed -$12.3M
IMGN
117
DELISTED
Immunogen Inc
IMGN
– –
-1,512,113
Closed -$24M
MRTX
118
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
– –
-2,024,226
Closed -$114M
SQZ
119
DELISTED
SQZ Biotechnologies Company
SQZ
– –
-1,606,309
Closed -$129K
1 2 3 4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q4 2023 Portfolio in Review

As of Q4 2023, Artal Group held 119 positions worth $3.01B, up 29% from $2.33B the previous quarter. Its ten largest holdings account for 75% of the portfolio.

Artal Group withdrew a net $168M in Q4 2023, closing 23 positions and reducing 26 holdings. Its most notable exit was Mirati Therapeutics, Inc. Common Stock, an estimated $114M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 50% of assets, down from 54% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in argenx worth $44.3M.

  • Artal Group's largest Q4 2023 buy was argenx: 116,388 shares worth $44.3M.
  • Artal Group added most to Scholar Rock in Q4 2023, an estimated $27.3M increase.
  • Artal Group's biggest Q4 2023 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $46.9M.
  • Artal Group fully exited Mirati Therapeutics, Inc. Common Stock in Q4 2023, selling an estimated $114M.
  • Artal Group's ten largest holdings make up 75% of its $3.01B portfolio in Q4 2023.
  • Artal Group opened 16 new positions and closed 23 in Q4 2023.
  • Artal Group's portfolio value rose 29% quarter-over-quarter to $3.01B.

Based on Artal Group's 13F filing for Q4 2023, filed 9 Feb 2024.